MedTrace Logo

Efficacy of INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT on Bone and Joint Health

NCT07658950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-06-22

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT improves joint health in adults aged 40-60 years with mild symptomatic knee osteoarthritis (defined by WOMAC total score 20-32 and knee pain VAS score 2-4). It will also assess the safety of the test product.

The main questions it aims to answer are:

Does the test product relieve knee pain, stiffness and physical activity difficulty measured by the WOMAC Osteoarthritis Index? Does the test product reduce pain intensity evaluated by the VAS Pain Scale? Can the test product improve 6-minute walking distance, sit-to-stand ability, stair-climbing performance and the range of motion of the hip and knee joints? What adverse reactions or safety issues do participants have when taking the test product? This is a single-arm, self-controlled clinical trial. Researchers will compare the test results of participants before and after taking the product to verify its efficacy in improving joint function.

Participants will:

Take 2 capsules of the test product once daily, 1 hour after meals, for 60 consecutive days Complete subjective efficacy evaluations, scale assessments and joint function tests at D3, D5, D14, D30, D40 and D60 Undergo safety follow-up tests of blood glucose, liver function and renal function at D56 Report joint symptoms and provide satisfaction feedback during the trial period

Conditions

  • Mild Knee Osteoarthritis (WOMAC 20-32, VAS 2-4)

Interventions

DIETARY_SUPPLEMENT

INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT

Take one pill at a time, twice a day, with meals or after meals

Sponsors & Collaborators

  • Guangzhou King Test Technology Co., Ltd.

    collaborator UNKNOWN

  • Hong Kong Junhuo Biotechnology Co., Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2026-03-12
Completion
2026-03-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07658950 on ClinicalTrials.gov